B+
Bull case
25%
Probability
Target price
$215.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
ICLR
ICONBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$190.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$150.00
Analysis reference price unavailable
Analysis 2026-10-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-28
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+45.1
Score
AI commentary
Initial coverage reported a 9.3% after-hours rise following the October 27 release, associated with bookings and guidance, but the October 28 earnings call and regular-hours reaction were still pending. Investing.com The stored earnings-document row concerns ALHC, not ICON, and was excluded. Post-print analyst revisions, options, short-interest, employee and social measures were not verified; zeroes in the sentiment fields mean unavailable, not neutral observations. The deterministic prior was negative with low evidence quality, so the confirmed release improves the operating picture without establishing a durable thesis reversal.
RankAlpha Sentiment Codex - 2026-10-28
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-10-28eventQ3 earnings-call digestionMedium impact
ICON reported $2.66 adjusted EPS and $2.025 billion revenue; Investing.com cited consensus of $2.64 and $2.01 billion. The October 28 call may clarify how bookings convert to revenue and whether higher pass-through activity improves underlying fees. [#PR-2026-10-27] ICON release
2026-12-31catalystRevised 2026 outlookMedium impact
ICON raised its revenue-guidance midpoint from $8.00 billion in July to $8.15 billion, while narrowing adjusted EPS guidance around an unchanged $10.50 midpoint. Management attributed the update partly to higher pass-through activity; the quality of that revenue increase remains a key test. [#PR-2026-10-27] Q3 release [#PR-2026-07-29] Q2 release
2027-06-30catalystBacklog conversion and margin recoveryHigh impact
Q3 net business wins were $3.15 billion, book-to-bill was 1.56x and backlog reached $24.5 billion. The longer-term test is conversion into direct-fee revenue and earnings: Q3 revenue fell 2.9% year over year and adjusted EBITDA fell 13.1%. [#PR-2026-10-27] ICON release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-28 • Updated nightlySource: Internal modelMethodology